TGF-beta in renal
allograft rejection. Miner Electrolyte Metab 1998; 24: 197-201.[CrossRef]
Cells mediating
allograft rejection. Transplantation 1991; 51: 1141-1151, doi: 10.1097/00007890-19910600000001.
This study explores the initial role and mechanism of ERCs in attenuating transplant vasculopathy following aorta allotransplantation, and it may provide a theoretical basis for the future clinical use of ERCs in preventing chronic
allograft rejection.
However, the frequency of CD4+IL-10+ T cells in the lymph nodes and spleens increased at the stage of corneal
allograft rejection. Therefore, the exact role of IL-10 in modulating immunological reaction in allogeneic corneal transplantation still needs to be confirmed by further studies.
Allograft rejection can be cell mediated or antibody mediated.
Interestingly, emerging data has shown that corneal
allograft rejection is not only dependent on frequencies of infiltrating T cells but is also associated with a distinct phenotype of T cells that are highly mobile within the allograft stroma [43].
HLA-B and HLA-B were coexpressed with 3135 (HLA-G major histocompatibility complex, class I, G) and 3134 (HLA-F major histocompatibility complex, class I, F) genes shared by many disease pathways, including HTLV-I infection, herpes simplex infection, Epstein-Barr virus infection, viral carcinogenesis, viral myocarditis, type I diabetes mellitus, graft-versus-host disease, autoimmune thyroid disease, and
allograft rejection (Table 3).
Antibody-mediated rejection criteria an addition to the banff 97 classification of renal
allograft rejection. Am J Transplant 2003;3(6):708-14.
The renal needle biopsies, though a mainstay for kidney transplant diagnosis of acute
allograft rejection, are invasive and are compromised by sampling heterogeneity and subjective interpretation.
It is an established invasive clinical tool used for surveillance of cardiac
allograft rejection and, to a lesser extent, in the evaluation of dilated and restrictive cardiomyopathies2.
The rate of
allograft rejection is not increased during pregnancy or 3 months postpartum and varies between 1 and 14.5%, which is comparable to nonpregnant transplant recipients [4, 22].